Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 9, 2012, Pages 857-865

  Sagel, Scott D ^a   Wagner, Brandie D ^b   Anthony, Margaret M ^a   Emmett, Peggy ^c   Zemanick, Edith T ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Cystic fibrosis; Inflammation; Neutrophil elastase; Pulmonary function; Sputum

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; NEUTROPHIL ELASTASE ALPHA1 ANTIPROTEASE COMPLEX; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; LUNG FUNCTION; MALE; NEUTROPHIL COUNT; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; RESPIRATORY TRACT INFLAMMATION; SCHOOL CHILD; SPUTUM;

BIOLOGICAL MARKERS; CHILD; CYSTIC FIBROSIS; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE ELASTASE; LUNG; MALE; PROSPECTIVE STUDIES; PROTEOLYSIS; SPUTUM;

EID: 84868296268     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201203-0507OC     Document Type: Article

References (37)

1. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill; 2001. pp. 521-588.
2. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453.
3. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
4. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001; 164:1425-1431.
5. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF Jr, Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985; 132:529-535.
6. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995;152:157-162.
7. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr 2002;141:811-817.
8. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005;39:224-232.
9. Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA. Levels of free granulocyte elastase in bronchial secre-tions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis 1986;153:902-909.
10. O'Connor CM, Gaffney K, Keane J, Southey A, Byrne N, O'Mahoney S, FitzGerald MX. Alpha 1-proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis 1993;148: 1665-1670.
11. Regelmann WE, Siefferman CM, Herron JM, Elliott GR, Clawson CC, Gray BH. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr Pulmonol 1995;19:1-9.
12. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pul-monary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-828.
13. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, et al. Risk fac-tors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-139.
14. Sagel SD, Anthony MM, Emmett P, Wagner BD. Longitudinal assessment of sputum biomarkers in school age children with cystic fibrosis. Am J Respir Crit Care Med 2011;183:A6118. (abstract).
15. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
16. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15: 75-88.
17. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163.
18. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
19. Jacqmin-Gadda H, Thiebaut R, Chene G, Commenges D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics 2000;1:355-368.
20. Thiebaut R, Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 2004;74:255-260.
21. Kim JS, Okamoto K, Rubin BK. Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis. Chest 2006;129:1148-1154.
22. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, Van Koningsbruggen S, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-725.
23. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-394.
24. Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006;29: 201-207.
25. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione pro-drug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006;103:4628-4633.
26. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fi-brosis. Pediatr Pulmonol 2006;41:177-183.
27. Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D. Alpha1-antitrypsin inhalation reduces airway inflamma-tion in cystic fibrosis patients. Eur Respir J 2007;29:240-250.
28. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-814.
29. Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L. Predictors of de-terioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33: 483-491.
30. Zemel BS, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 2000;137:374-380.
31. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-1049.
32. Ellway JE, Zemanick ET, Towler E, Sagel SD. Clinical value of sputum induction to diagnose infection in cystic fibrosis [abstract]. Am J Respir Crit Care Med 2011;183:A1129.
33. Al Saleh S, Dell SD, Grasemann H, Yau YC, Waters V, Martin S, Ratjen F. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr 2010;157:1006-1011.
34. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007;4:406-417.
35. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008;178:822-831.
36. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. Sputum and serum calprotectin are useful biomarkers during CF ex-acerbation. J Cyst Fibros 2010;9:193-198.
37. Coakley RD, Sun H, Clunes LA, Rasmussen JE, Stackhouse JR, Okada SF, Fricks I, Young SL, Tarran R. 17beta-estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. J Clin Invest 2008;118:4025-4035.